Compare DexCom, Inc. (DXCM) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Mondaycom Ltd — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Mondaycom Ltd trades at $88.92 (market cap $3.76B). The key difference: DexCom, Inc. is far larger — about 8.5× Mondaycom Ltd's market cap, and DexCom, Inc. is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Mondaycom Ltd for 16 Days on average.
| DXCM | MNDY | |
|---|---|---|
Market Cap | $31.86B | $3.76B |
Volume | 3,607,070 | 836,200 |
Sector | Health | Technology |
52-Week High | $92.34 | $205.24 |
52-Week Low | $54.84 | $58.81 |
Typical Hold Time | 62 Days | 16 Days |
Enterprise Value | $31.32B | $2.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
Monday.com (MNDY) trades at $88.96, up 6.53% in the last session, showing strong momentum after recent earnings beats. The stock maintains bullish technical signals with support at $86 and resistance at $90. Fundamentally, the company demonstrates robust revenue growth reaching $1.23 billion in 2025 with impressive 88.74% gross margins, though valuation multiples remain elevated with a P/E of 37.69. Recent news highlights the company's AI initiatives at its Elevate '26 conference and inclusion in multiple growth stock lists.
The outlook remains positive with Wall Street consensus at $108.64 target price and 65% buy ratings, though risks include competitive pressure from Meta's enterprise push and elevated valuation multiples. Earnings momentum continues with three consecutive quarterly beats, but investors should monitor the upcoming Q3 2026 results against $1.37 EPS expectations for continued validation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
